Home | Eli and Edythe Broad Center of Regeneration …
California’s Stem Cell Agency | California Institute for …
In more than 140 labs across UCSF, scientists are carrying out studies in cell culture and animals with the goal of understanding and developing treatment strategies for such conditions as heart disease, diabetes, epilepsy, multiple sclerosis, Parkinsons disease, Lou Gehrigs disease, spinal cord injury and cancer. The Broad Center is structured around eight research pipelines aimed at driving discoveries from the lab bench to the patient. Each pipeline focuses on a different organ system, including the blood, pancreas, liver, heart, reproductive organs, nervous system, musculoskeletal tissues, skin and eyes.
Stem Cell & Regenerative Medicine Center University of …
CIRMTown Hall,Tuesday June 29, 2021 Click here to register via Zoom ICOC Governing Board/Application Review Subcommittee, TuesdayApril20, 2021 ICOC Governing Board/Application Review Subcommittee,Tuesday, March 23, 2021 ICOC Governing Board/Application Review Subcommittee,Thursday, February 25, 2021 Scientific Strategy Advisory Panel meets with ICOC, Monday, February 22, 2021 CIRM Webinar with Moderna Co-Founder Derrick Rossi, Wednesday, January 27, 2021
Special type of stem cell can reduce the amount of HIV virus – News-Medical.Net
UW Begins New Clinical Trial to Treat Fatal Blood Disease in Children, Young Adults The Food and Drug Administration-approved trial will use a form of transplant that replaces a patients bone marrow with alpha-beta T-cell depleted peripheral blood stem cells from closely matched unrelated donors or family members. May 27, 2021 Over the past two decades, stem cell research at UW-Madison has grown from involving a handful of scientists to nearly 100 from more than 30 schools, colleges and departments
Join the World Stem Cell Summit for a virtual conference …
In a groundbreaking study, a team of UC Davis researchers has discovered a special type of stem cell that can reduce the amount of the virus causing AIDS, boosting the body's antiviral immunity and repairing and restoring the gut's lymphoid follicles damaged by the simian immunodeficiency virus (SIV), the equivalent of the human immunodeficiency virus (HIV) in non-human primates. The study, published June 22 in JCI Insight, showed the mechanism through which mesenchymal stem/stromal cells (MSCs) enhance the body's immune response to the virus
Novel Tafasitamab Combination Finds a Role in Second-line DLBCL Treatment – Targeted Oncology
Every year Bernie Siegel and his team at the World Stem Cell Summit (WSCS) put together a conference that highlights various topics in the stem cell and regenerative medicine field. This year, because of the coronavirus pandemic, the conference has adopted an entirely virtual format
Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat…
Targeted OncologyTM: What are the approved treatment options for such a patient in the second-line setting? What disease characteristics would help to determine which regimen should be used
Discrepancies Between Real-World Patterns of Care and Recommendations Based on Clinical Trials Exist in MCL – OncLive
BALTIMORE, Md.--(BUSINESS WIRE)--Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies that follow an autologous and universal hypoimmunogenic approach, today announced the completion of an oversubscribed $32 million Series A. The financing was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.
Immusoft Announces Formation of Scientific Advisory Board – Business Wire
Results from a retrospective, observational study, presented during the 2021 ASCO Annual Meeting, showed that such discrepancies were notable in patients aged 65 years and younger, in that only 30.5% were treated with a cytarabine-containing chemotherapy regimen, and 23.3% underwent stem cell transplant. Additionally, among patients who were aged 65 years or older, approximately 65% received treatment with bendamustine and rituximab (Rituxan) or R-CHOP. Moreover, the real-world median time to next treatment for patients younger than 65 years was 28 months and 22.3 months in patients older than 65 years, which appeared worse than what has been reported with standard therapies in this population
World Sickle Cell Day: Symptoms and treatment options for Sickle Cell Disease – Times of India
SEATTLE--(BUSINESS WIRE)--Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Companys research and development programs. The SAB will work closely with the Immusoft leadership team to advance and expand its leadership position in B cells as biofactories for therapeutic protein delivery, a novel approach that Immusoft has pioneered. The Company is currently preparing for the near-term clinical development of its lead investigational drug candidate ISP-001, a first-in-class investigational treatment for Hurler syndrome, the most severe form of mucopolysaccharidosis type 1 (MPS I), a rare lysosomal storage disease
Sickle cell disease (SCD) is an inherited health condition and one of the most common blood disorders globally. In India, over 1 million people are affected by sickle cell disease every year; geographically, there is a sickle cell belt that comprises of some tribal communities in Madhya Pradesh, Chhattisgarh, Maharashtra, Kerala, Gujarat, Tamilnadu, and Odisha.World Sickle Cell day is observed every year on June 19thto raise awareness about sickle cell disease, itschallenges and treatment options.Sickle cell disease (SCD) is a group of blood disorders inherited by a child from its parents.The most common type of sickle cell disease is known as Sickle Cell Anaemia,an abnormality in the oxygen-carrying protein (hemoglobin) in red blood cells.